Dosage of Nivolumab

1. (1) Unresectable or metastatic melanoma:

When used as a single agent, the recommended dose of Nivolumab is 240 mg intravenously over 30 minutes every 2 weeks or 480 mg intravenously over 30 minutes every 4 weeks until disease progression or unacceptable toxicity; when used in combination with ipilimumab, 1 mg/kg intravenously over 30 minutes every 3 weeks and 3 mg/kg intravenously over 90 minutes on the same day ipilimumab, given as a single agent or 480 mg intravenously over 30 minutes every 2 weeks for up to 4 doses or until unacceptable toxicity, whichever occurs first; after completion of 4 doses of combination therapy, as a single agent or 480 mg intravenously over 30 minutes every 4 weeks; after completion of 4 doses of combination therapy, as a single agent until disease progression or unacceptable toxicity.

(2) Adjuvant treatment of melanoma: The recommended dose of nivolumab is 240 mg intravenously over 30 minutes every 2 weeks or 480 mg intravenously over 30 minutes every 4 weeks until disease progression or unacceptable toxicity for one year.

2. Non-small cell lung cancer:

(1) Metastatic non-small cell lung cancer: The recommended dose of nivolumab is 240 mg intravenously over 30 minutes every 2 weeks or 480 mg intravenously over 30 minutes every 4 weeks until disease progression or unacceptable toxicity occurs.

(2) in combination with ipilimumab for the treatment of metastatic or recurrent non-small cell lung cancer expressing PD-L1:

Nivolumab 3 mg/kg intravenously over 30 minutes every and 1 mg/kg intravenously over 30 minutes every 6 weeks for ipilimumab until disease progression, unacceptable toxicity, or up to 2 years in patients without disease progression.

(3) Combination treatment for metastatic or recurrent non-small cell lung cancer: In the first 2 cycles, 360 mg intravenously over 30 minutes every 3 weeks, 1 mg/kg ipilimumab intravenously over 30 minutes every 6 weeks, followed by histology-based platinum doublet chemotherapy every 3 weeks, then 360 mg intravenously over 30 minutes every 3 weeks, and 1 mg/kg intravenously over 30 minutes every 6 weeks ipilimumab until disease progression, unacceptable toxicity, or up to 2 years in patients without disease progression.

3. Malignant pleural mesothelioma: When used in combination withipilimumab, the recommended dose of nivolumab is 360 mg intravenously over 30 minutes every 3 weeks and 1 mg/kgipilimumab intravenously over 30 minutes every 6 weeks until disease progression, unacceptable toxicity, or up to 2 years in patients without disease progression.

4. Renal cell carcinoma:

（1) Monotherapy: Nivolumab 240 mg intravenously over 30 minutes every 2 weeks or 480 mg intravenously over 30 minutes every 4 weeks until disease progression or unacceptable toxicity.

(2) In combination with ipilimumab: nivolumab 3 mg/kg intravenously over 30 minutes every 3 weeks, and ipilimumab 1 mg/kg intravenously over 30 minutes on the same day, for a total of 4 doses. Then after completion of 4 doses of combination therapy, give as single agent: 240 mg intravenously over 30 minutes every 2 weeks or 480 mg intravenously over 30 minutes every 4 weeks until disease progression, unacceptable toxicity, or up to 2 years.

(3) In combination with cabozantinib: Nivolumab 240 mg intravenously over 30 minutes every 2 weeks in combination with cabozantinib 40 mg orally once daily (without food) until disease progression or unacceptable toxicity occurs. After completing 4 doses of ipilimumab combination therapy, nivolumab was administered as a single agent until disease progression or unacceptable toxicity.

5. Classic Hodgkin lymphoma, squamous cell carcinoma of the head and neck (SCCHN), and urothelial carcinoma (UC): The recommended dose of nivolumab is 240 mg intravenously over 30 minutes every 2 weeks or 480 mg intravenously over 30 minutes every 4 weeks until the disease worsens or unacceptable toxicity occurs.

6. Colorectal cancer (CRC), hepatocellular carcinoma: 40 kg or more

(1) Monotherapy: The recommended dose of nivolumab is 240 mg intravenously over 30 minutes every 2 weeks or 480 mg intravenously over 30 minutes every 4 weeks until disease progression or unacceptable toxicity occurs.

(2) In combination with ipilimumab: After completing 4 doses of combination therapy, 3 mg/kg intravenously over 30 minutes every 3 weeks and 1 mg/kg intravenously over 30 minutes on the same day for a total of 4 doses, as a single agent, 240 mg intravenously over 30 minutes every 2 weeks or 480 mg intravenously over 30 minutes every 4 weeks until disease progression or unacceptable toxicity.

7. Esophageal cancer and gastric cancer:

(1) Monotherapy: Nivolumab 240 mg intravenously over 30 minutes every 2 weeks or 480 mg intravenously over 30 minutes every 4 weeks until disease progression or unacceptable toxicity or for a total treatment duration of 1 year.

(2) Combined use: 240 mg intravenously over 30 minutes every 2 weeks or 360 mg fluoropyrimidine and platinum-containing chemotherapy drugs intravenously over 30 minutes every 3 weeks until disease progression, unacceptable toxicity, or up to 2 years.

The generic drug Nivolumab is currently on the market in China, but it has not yet been included in medical insurance. This drug is a strictly controlled drug, and its purchase channels are restricted. Specifications The price of each box of 40mg/4ml may be around RMB 4,000. The Turkish version of the nivolumab generic drug listed overseas may cost more than RMB 2,000 per box of 40mg/4ml (the price may fluctuate due to exchange rates). Currently, there is no generic version of nivolumab available on the market. For more drug information and specific prices, please consult a medical consultant.